ClinicalTrials.gg
CompletedNCT05753956Updated Jan 25, 2024

Safety and Pharmacokinetics of GH002 in Healthy Volunteers

A Phase 1 interventional study of 5 Methoxy N,N Dimethyltryptamine and Placebo in Healthy Volunteers, sponsored by GH Research Ireland Limited. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-25.

Sponsored by GH Research Ireland Limited · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

The primary objectives of this study are to investigate the safety and serum pharmacokinetics of 5-MeO-DMT in healthy volunteers in a double-blind, placebo-controlled, randomized study design with single, injected doses of GH002 and in an open-label, non-randomized study design with intra-subject dose-escalation of GH002. As secondary objectives, the PK/ pharmacodynamic relationship, PD profile of GH002 as evaluated by its psychoactive effects and impact on cognitive performance, and the serum PK of the metabolite bufotenine are also assessed.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • 5-MeO-DMT
  • 5-methoxy-N,N-dimethyltryptamine
  • Healthy Volunteers
  • Pharmacokinetics
  • Mebufotenin
03

In context

Lead sponsor

GH Research Ireland Limited is the lead sponsor of 9 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a (BMI) in the range of 18.5 and 35 kg/m2 (inclusive) at Screening.
  • Is deemed in good physical health by the investigator.
  • Is in good mental health in the opinion of the investigator and clinical psychologist

Exclusion criteria

Exclusion Criteria:

  • Has known allergies or or any other to 5-MeO-DMT.
  • Has received any medication, including investigational vaccines, within the 6 weeks prior to baseline
  • Has a current or past condition, which renders the subject unsuitable for the trial according to the Investigator's judgement.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    Cohort A: Dose A single dose

    A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)

    Drug: 5 Methoxy N,N Dimethyltryptamine · Drug: Placebo

  • Experimental
    Cohort B: Dose B single dose

    A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)

    Drug: 5 Methoxy N,N Dimethyltryptamine · Drug: Placebo

  • Experimental
    Cohort C: Dose C single dose

    A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)

    Drug: 5 Methoxy N,N Dimethyltryptamine · Drug: Placebo

  • Experimental
    Cohort D: Dose D single dose

    A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)

    Drug: 5 Methoxy N,N Dimethyltryptamine · Drug: Placebo

  • Experimental
    Cohort E: Dose E single dose

    A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)

    Drug: 5 Methoxy N,N Dimethyltryptamine · Drug: Placebo

  • Experimental
    Cohort F: Dose F single dose

    A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)

    Drug: 5 Methoxy N,N Dimethyltryptamine · Drug: Placebo

  • Experimental
    Cohort G: Dose G single dose

    A single dose of GH002 or placebo administered by i.v. bolus injection (randomized as 6 active and 2 placebo subjects)

    Drug: 5 Methoxy N,N Dimethyltryptamine · Drug: Placebo

  • Experimental
    Cohort J: Individualized Dosing Regimen

    Administration of up to 3 doses of GH002 within a single day (doses to be confirmed following review of data from single-dose part)

    Drug: 5 Methoxy N,N Dimethyltryptamine

Interventions

  • GH002 administered via i.v. bolus injection(s)

    Also known as: GH002, 5-MeO-DMT

  • DrugPlacebo

    GH002 placebo administered via i.v. bolus injection

    Also known as: GH002 placebo

06

What researchers measure

Primary outcomes

  1. Safety and tolerability: incidence of treatment emergent adverse events

    Adverse events reported in the study and coded by MedDRA.

    Time frame: Up to 7 days

  2. Safety and tolerability: local tolerance (injection site reactions)

    Local infusion site findings will be assessed as none, mild, moderate and severe for the following signs and symptoms of the applicable site: dryness, redness, swelling, pain, tenderness, and itching and other.

    Time frame: Up to discharge on dosing day

  3. Safety and tolerability: Clinically significant changes from baseline in ECG, vital signs and safety laboratory assessments

    Clinically significant changes in ECG include any significant change in rate or rhythm as determined by the principal investigator

    Time frame: Up to 7 days

  4. Safety and tolerability: Assessment of sedation (Modified Observer's Assessment of Alertness and Sedation [MOAA/S]) following each dose and as part of the discharge evaluation on Day 0

    The Modified Observer's Assessment of Alertness and Sedation scale (MOAA/S) will be completed before and after GH002 dosing. Scored from 0 (deep sedation) to 5 (alert)

    Time frame: Up to discharge on dosing day

  5. Safety and tolerability: Change from baseline in Clinician Administered Dissociative States Scale (CADSS)

    The CADSS comprises 19 subjective items, ranging from 0 'not at all' to 4 'extremely. Summed together, these subscales form a total dissociative score. Combined score ranges from 0 to 76

    Time frame: Up to 7 days

  6. Safety and tolerability: Assessment of subject-discharge readiness at discharge on Day 0

    Assessment of Discharge Readiness on the administration day by the Principal Investigator, using the Clinical Assessment of Discharge Readiness (CADR).

    Time frame: Up to discharge on dosing day

  7. Safety and tolerability: Columbia-Suicide Severity Rating Scale (C-SSRS) categorization based on the Columbia Classification Algorithm of Suicide Assessment (C-CASA).

    A detailed questionnaire assessing both suicidal behaviour and suicidal ideation.

    Time frame: Up to 7 days

  8. Safety and tolerability: Change from baseline in Brief Psychiatric Rating Scale (BPRS).

    A scale to measure psychiatric symptoms. Each symptom is rated 1-7 and a total of 18 symptoms are scored. Combined score ranges from 18 to 126.

    Time frame: Up to 7 days

  9. The pharmacokinetic (PK) parameters derived from laboratory assay results of the systemic levels of 5-MeO-DMT

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH002 to determine 5-MeO-DMT serum concentrations.

    Time frame: Up to 6 hours

Secondary outcomes

  1. Pharmacodynamic assessment: The dose-related psychoactive effects of GH002 as evaluated by a Visual Analogue Scale

    The Peak Experience Scale (PES) is a Visual Analogue Scale scored from 0-100

    Time frame: Up to 1 hour after dosing

  2. Pharmacodynamic assessment: Challenging Experiences Questionnaire (CEQ)

    Completed by the subject after GH002 administration and assesses seven factors (grief, fear, death, insanity, isolation, physical distress, and paranoia) all scored from 0 to 5.

    Time frame: Up to 1 hour after dosing

  3. Pharmacodynamic assessment: 30-Question Mystical Experience Questionnaire (MEQ30)

    The MEQ30 is a validated procedure for assessing the extent of the psychoactive effects experienced by a subject. The validated MEQ30 uses thirty assessment questions across four areas of experience, all scored from 0 to 5.

    Time frame: Up to 1 hour after dosing

  4. Pharmacodynamic assessment: Duration of the psychoactive effects (PsE)

    The duration of the experience, defined as time in minutes from drug administration to time when the subject reports that any psychoactive symptoms have subsided will be recorded.

    Time frame: Up to 1 hour after dosing

  5. PK/PD relationship(s) of 5-MeO-DMT

    In particular the correlation between Cmax and AUC with PES score and duration of PsE as scored by the investigator will be described

    Time frame: Up to 1 hour after dosing

  6. Cognitive Function: Change from baseline in Rapid visual information processing (RVP) test

    A computerized test assessing the reaction time in response to a visual stimulus.

    Time frame: Up to 7 days

  7. Cognitive Function: Change from baseline in Verbal recognition memory (VRM) test

    The VRM test is based on successive auditory presentations of 18-word lists followed by attempted recall.

    Time frame: Up to 7 days

  8. Cognitive Function: Change from baseline in Spatial Working Memory (SWM) task

    The SWM test requires retention and manipulation of visuospatial information. This test has notable executive function demands, and measures strategy use as well as errors. In this task the subject has to search for tokens hidden in boxes on screen. The subject must touch a box to open the box to reveal either a yellow token or an empty box. Once the subject has found a yellow token, they must touch the outline of the right-hand side of the screen to 'store' it. The subject must then continue searching through the boxes until all of the tokens have been found. The test takes about 4 minutes to complete

    Time frame: Up to 7 days

  9. Cognitive Function: Change from baseline in Digit Symbol Substitution Task (DSST)

    The DSST is a global measure of cognitive ability, requiring the engagement of multiple cognitive domains in order to complete effectively. A computerized test with the task is to match digits with symbols from encoding list. The number of digits correctly encoded within 90 seconds is the performance measure.

    Time frame: Up to 7 days

  10. The pharmacokinetic (PK) parameters derived from laboratory assay results of the systemic levels of bufotenine

    For PK analyses, blood samples will be collected before and up to 6 hours after the administration of GH002 to determine bufotenine serum concentrations.

    Time frame: Up to 6 hours

07

Study locations

1 site
  • GH Research Clinical Trial Site
    Groningen, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2022 to primary completion in Nov 2023, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 23, 2023
First posted
Mar 3, 2023
StartActual
Dec 22, 2022
Primary completionActual
Nov 29, 2023
CompletionActual
Nov 29, 2023
Last update
Jan 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05753956
Lead sponsor
GH Research Ireland Limited
Responsible party
Sponsor
First posted
Mar 3, 2023
Start date
Dec 22, 2022
Primary completion
Nov 29, 2023
Completion
Nov 29, 2023
Last update
Jan 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxydimethyltryptamines

Start the discussion